Evidence supporting the use of: Tetrahydrocannabinol
For the health condition: Wasting

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, has scientific evidence supporting its use in the management of wasting syndrome, particularly in the context of HIV/AIDS and cancer. Wasting syndrome, characterized by unintended weight loss and muscle atrophy, is a serious complication in these conditions.

Several randomized controlled trials have demonstrated that THC and synthetic cannabinoids such as dronabinol can stimulate appetite, increase caloric intake, and promote weight gain in patients experiencing anorexia and cachexia (wasting). The U.S. Food and Drug Administration (FDA) has approved dronabinol (a synthetic form of THC) for the treatment of anorexia associated with weight loss in patients with AIDS, based on clinical trial data showing modest, but statistically significant, improvements in appetite and stabilization or slight increases in body weight.

The mechanism is thought to involve THC's action on the endocannabinoid system, which plays a role in regulating appetite and energy balance. While the effect size is moderate and not all patients respond, the evidence base is sufficient for clinical use in selected cases. However, THC is not universally effective for all causes of wasting, and side effects such as dizziness and cognitive impairment may limit tolerability for some individuals.

In summary, the use of THC for wasting is supported by moderate-quality scientific evidence, particularly in HIV/AIDS-related anorexia, and is recognized by regulatory agencies in specific clinical contexts.

More about Tetrahydrocannabinol
More about Wasting

Products containing Tetrahydrocannabinol

We currently have no products on Vitabase that contain this ingredient.